Catatan sumber primer
MaterialPermohonan diterima
Boundless Bio: FDA menerima IND untuk BBI-940 Kinesin degrader
FDA menerima IND untuk BBI-940 pada Januari 2026, memungkinkan uji coba KOMODO-1 first-in-human dibuka untuk pendaftaran pada kanker payudara ER+/HER2- dan TNBC-LAR. Perusahaan kini memiliki program klinis aktif dengan runway kas hingga H2 2028 yang mencakup pembacaan bukti konsep awal yang diharapkan.
Fakta utama
- Diajukan
- 9 Mar 2026, 11.05
- Peristiwa
- Permohonan diterima
- Arah
- Positif
- Perusahaan
BOLDBoundless Bio, Inc.- Aset
- BBI-940
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 bold-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 – Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited